Emergent dynamics of underlying regulatory network links EMT and androgen receptor-dependent resistance in prostate cancer.

ABSTRACT: Advanced prostate cancer patients initially respond to hormone therapy, be it in the form of androgen deprivation therapy or second-generation hormone therapies, such as abiraterone acetate or enzalutamide. However, most men with prostate cancer eventually develop hormone therapy resistance. This resistance can arise through multiple mechanisms, such as through genetic mutations, epigenetic mechanisms, or through non-genetic pathways, such as lineage plasticity along epithelial-mesenchymal or neuroendocrine-like axes. These mechanisms of hormone therapy resistance often co-exist within a single patient's tumor and can overlap within a single cell. There exists a growing need to better understand how phenotypic heterogeneity and plasticity results from emergent dynamics of the regulatory ne

SUBMITTER: Jindal R 

PROVIDER: S-EPMC9957767 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature